Pharma BD Deal Intelligence

Allergan plc / ForSight VISION5, Inc.

2016 · Acquisition/Merger · $95M · Complete

Announcement Sentiment

Strongly positive

Allergan acquired ForSight VISION5, a clinical-stage eye care biotech, for ~$95M all-cash. Lead asset was a sustained-release bimatoprost periocular ring for glaucoma/ocular hypertension. Strengthened Allergan's eye care pipeline alongside Restasis franchise.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Sep 23, 2016
Closed Sep 23, 2016
Deal value $95M
Deal type Acquisition/Merger
Therapeutic area Glaucoma / ocular hypertension
Indications Glaucoma / ocular hypertension
Key assets Bimatoprost periocular ring
Mechanism Sustained-release bimatoprost (prostaglandin analog) periocular delivery

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals